Aprea Therapeutics, Inc. (APRE)
APRE Stock Price Chart
Explore Aprea Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze APRE price movements and trends.
APRE Company Profile
Discover essential business fundamentals and corporate details for Aprea Therapeutics, Inc. (APRE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Oct 2019
Employees
8.00
Website
https://atrinpharma.comCEO
Oren Gilad
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
APRE Financial Timeline
Browse a chronological timeline of Aprea Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Mar 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.11.
Earnings released on 12 Aug 2025
EPS came in at -$0.53 surpassing the estimated -$0.77 by +31.17%, while revenue for the quarter reached $118.11K .
Earnings released on 14 May 2025
EPS came in at -$0.66 falling short of the estimated -$0.65 by -0.87%, while revenue for the quarter reached $162.46K .
Earnings released on 25 Mar 2025
EPS came in at -$0.49 surpassing the estimated -$0.69 by +28.99%, while revenue for the quarter reached $205.82K , missing expectations by -8.53%.
Earnings released on 7 Nov 2024
EPS came in at -$0.64 surpassing the estimated -$0.75 by +14.67%, while revenue for the quarter reached $354.62K , beating expectations by +57.61%.
Earnings released on 12 Aug 2024
EPS came in at -$0.58 surpassing the estimated -$0.64 by +9.38%, while revenue for the quarter reached $561.57K , beating expectations by +1.02K%.
Earnings released on 14 May 2024
EPS came in at -$0.67 surpassing the estimated -$0.78 by +14.10%, while revenue for the quarter reached $380.57K .
Earnings released on 26 Mar 2024
EPS came in at -$0.92 falling short of the estimated -$0.56 by -64.29%, while revenue for the quarter reached $14.08K , missing expectations by -87.20%.
Earnings released on 9 Nov 2023
EPS came in at -$0.86 surpassing the estimated -$1.08 by +20.37%, while revenue for the quarter reached $319.47K , beating expectations by +190.43%.
Earnings released on 10 Aug 2023
EPS came in at -$0.87 surpassing the estimated -$1.43 by +39.16%, while revenue for the quarter reached $249.69K .
Earnings released on 15 May 2023
EPS came in at -$1.34 surpassing the estimated -$1.51 by +11.26%.
Earnings released on 30 Mar 2023
EPS came in at -$0.92 surpassing the estimated -$2.60 by +64.62%.
Stock split effective on 13 Feb 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2022
EPS came in at -$2.40 surpassing the estimated -$5.60 by +57.14%.
Earnings released on 11 Aug 2022
EPS came in at -$19.80 falling short of the estimated -$7.60 by -160.53%.
Earnings released on 16 May 2022
EPS came in at -$7.20 surpassing the estimated -$7.60 by +5.26%.
Earnings released on 15 Mar 2022
EPS came in at -$7.20 surpassing the estimated -$8.80 by +18.18%.
Earnings released on 8 Nov 2021
EPS came in at -$9.00 falling short of the estimated -$8.80 by -2.27%.
Earnings released on 12 Aug 2021
EPS came in at -$9.60 falling short of the estimated -$9.40 by -2.13%.
Earnings released on 6 May 2021
EPS came in at -$9.20 surpassing the estimated -$10.40 by +11.54%.
Earnings released on 16 Mar 2021
EPS came in at -$14.60 falling short of the estimated -$12.60 by -15.87%.
Earnings released on 5 Nov 2020
EPS came in at -$11.60 surpassing the estimated -$15.40 by +24.68%.
APRE Stock Performance
Access detailed APRE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.